Neustar Expands European Data Scrubbing Estate to Build the World’s Largest DDoS Mitigation Defence Network
Neustar, Inc. (NYSE: NSR), a trusted, neutral provider of real-time information services, today announced the expansion of its DDoS mitigation defence network in EMEA. Scrubbing centres in London, Frankfurt, Amsterdam and Marseille have been expanded, while new facilities in Stockholm and Tokyo have gone live.
The new scrubbing centres were deployed in partnership with Arbor Networks to deliver the world’s largest, most distributed and technically advanced DDoS mitigation defence network.
Through to mid-2018, the Neustar Global DDoS Defence Network will continue to grow its scrubbing capacity, with scrubbing centres distributed across all regions. This will provide unequalled capacity, underpinned by the best mitigation technology available in market, and over 15 years of mitigation experience.
“As part of Neustar’s quest to end the DDoS attack arms race, the construction of our enhanced network with regionalised nodes is a game-changer for our customers”, said Barrett Lyon, General Manager, DDoS Defence, Neustar. “We are continually futureproofing the network to meet and defeat new attacks head-on, with enhanced and localised scrubbing. Put another way, unlike anything else available on the market today, Neustar is building a constantly evolving network that delivers clients with the required level of sophisticated DDoS defence capabilities needed to defend against the attacks of tomorrow,” Lyon added.
The Neustar Global DDoS Defence Network is integrated with the Neustar Web Application Firewall (WAF), protecting against sophisticated application layer attacks. The combination of technologies delivers multi-layered protection against the most aggressive and sophisticated attacks seen today.
The addition of the new nodes will mean a total network capacity exceeding any other DDoS mitigation network and achieve Neustar’s vision of providing a network that enables unrivalled mitigation capability and network performance, keeping its customers protected against any type of DDoS attack.
Neustar’s security solution, SiteProtect NG, breaks with the tradition of designing network protection that makes use of a high volume of small scrubbing centres with fewer, highly fortified and highly connected locations. SiteProtect NG network has deployed large, full scale, nodes, each with its multi-terabit scrubbing capacity in North America, Europe, and Asia with South America, Africa, Australia, and India slated for early 2018.
About Neustar Security Solutions
Neustar Security Solutions defend against network threats, inform you of potential network vulnerabilities, accelerate online asset performance, and monitor client website performance through multiple services and offerings. Neustar’s industry leading SiteProtect NG DDoS defense service ensures full layered coverage in an attack. Neustar UltraDNS service manages 10% of all internet traffic, routes over 1 trillion queries a month and provides industry leading uptime with 100% availability. Neustar IP Intelligence is the authoritative source of IP decisioning data on 99.99% of routable IP addresses worldwide. Our nearly 20 years of unparalleled expertise ensures that our customers are protected and optimized during normal business practices and when unsolicited events occur. Our services ensure customers network connectivity are protected and optimized whether in crisis or just business as usual. We are trusted by many of the world’s largest brands to keep their mission critical systems up and running. More information is available at www.security.neustar.
About Neustar
Neustar, Inc. is a leading global information services provider driving the connected world forward with trusted, holistic identity resolution. As the only company capable of understanding who is on the other end of every interaction, Neustar is trusted by the world’s great brands to grow and guard their businesses with the most complete knowledge of how to connect people, places and things. The combination of Neustar’s unique, accurate, and real-time identity system and our cloud-based workflow solutions empower our clients to make actionable, precise and valuable decisions across marketing, risk, IT/security, network & operations departments. As the sole provider of the U.S. Number Portability Administration Centre, Neustar also facilitates the routing of all telephone call and text messages in the U.S. More information is available at https://www.home.neustar.
Arbor Networks is a service mark of its owners and are used with permission.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: http://www.businesswire.com/news/home/20180209005027/en/
Contact information
Media contact:
Hannah Lock
Hotwire for Neustar
neustar@hotwirepr.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Receives CHMP Positive Opinion for ALYFTREK ® , a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis28.4.2025 09:03:00 EEST | Press release
Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor)for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “Our goal has always been to serially innovate to help people with cystic fibrosis live healthier and longer lives. If approved, this new medicine would be indicated for people with CF ages 6 years and older with at least one non-class I mutation, meaning more patients would be eligible for a medicine that gets them closer to normal levels of sweat chloride,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. “CFTR modulators have already revolutionized the way we treat CF and I am encoura
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 08:02:00 EEST | Press release
Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization and further development of pridopidine in Europe and other select markets. Pridopidine is a potent and highly selective, orally administered sigma-1 receptor (S1R) agonist designed to regulate key neuroprotective mechanisms often impaired in neurodegenerative diseases such as HD and ALS. Under the terms of the agreement, Prilenia will receive an upfront payment of approximately €80 million plus up to €45 million in near-term development, regulatory, and commercial milestones. The total deal is valued at up to approximately €500 million in upfront and total milestone payments. In addition, Prilenia will receive tiered double-digit royalties on
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 08:00:00 EEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 12:36:00 EEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 20:00:00 EEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom